Delve Detect
Meningitis and Encephalitis (CNS Infections)
CommercialActive
Key Facts
About Delve Bio
Delve Bio is a commercial-stage diagnostics company commercializing a powerful mNGS platform for the agnostic detection of pathogens in infectious diseases, starting with CNS infections. Its Delve Detect test demonstrates a 22% greater diagnostic yield than conventional methods, with results in 48 hours, backed by real-world evidence from over 4,800 patient samples. The company leverages a proprietary bioinformatics platform (Delve Decide) and a strategic partnership with Broad Clinical Labs for sequencing, positioning itself to address critical gaps in the diagnosis of routine and rare infections.
View full company profile